Lutetium Lu177 Edotreotide

Generic Name: Lutetium Lu177 Edotreotide

Drug Type: Small Molecule

Chemical Formula: C_₆₅H_₈₉LuN_₁₄O_₁₈S_₂

CAS Number: 321835-55-6

Unique Ingredient Identifier: RGO812Q0C8

Clinical Trials

Phase I Trial to Determine the Dose and Evaluate the PK of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors

Phase 1

Not yet recruiting

Conditions: NET
Lymphoma
Solid Tumor, Childhood
Somatostatin Receptor Positive
CNS Tumor

Interventions: Drug: Lutetium Lu 177-Edotreotide
Other: Amino Acid Solution

First Posted Date: 2024-06-04

Last Posted Date: 2024-12-02

Lead Sponsor: ITM Solucin GmbH

Target Recruit Count: 20

Registration Number: NCT06441331

"Receptor Radionuclide Therapy With 177Lu-DOTATOC

Phase 2

Recruiting

Conditions: Neuroendocrine Tumors
Paraganglioma
Pheochromocytoma

Interventions: Drug: 177Lu-DOTATOC

First Posted Date: 2023-09-21

Last Posted Date: 2024-08-13

Lead Sponsor: Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori

Target Recruit Count: 100

Registration Number: NCT06045260

Locations: 🇮🇹
AUSL Romagna - Ospedale "M. Bufalini", Cesena, Forlì-Cesena, Italy
🇮🇹
IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST S.r.l., Meldola, Forlì-Cesena, Italy

Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.

Phase 3

Recruiting

Conditions: Thymus Neoplasms
Neuroendocrine Tumors
Lung Neuroendocrine Neoplasm

Interventions: Drug: 177Lu-edotreotide
Drug: Everolimus

First Posted Date: 2023-06-26

Last Posted Date: 2024-11-11

Lead Sponsor: Grupo Espanol de Tumores Neuroendocrinos

Target Recruit Count: 120

Registration Number: NCT05918302

Locations: 🇫🇷
Centre Hospitalier Universitaire (CHU) Bordeux, Bourdeaux, France
🇫🇷
Hospital Center University Dijon Bourgogne (CHU Bourgogne), Dijon, France
🇫🇷
Lille University Hospital, Lille, France

and more 23 locations

Systemic Targeted Adaptive RadioTherapy of NeuroEndocrine Tumors.

Phase 3

Recruiting

Conditions: Neuroendocrine Tumors

Interventions: Drug: 177Lu-DOTATOC
Drug: Capecitabine

First Posted Date: 2022-05-24

Last Posted Date: 2024-08-20

Lead Sponsor: Lund University Hospital

Target Recruit Count: 300

Registration Number: NCT05387603

Locations: 🇸🇪
Sahlgrenska University Hospital, Dept. of Oncology, Göteborg, Sweden
🇸🇪
Karolinska University Hospital, Dept. of Oncology, Stockholm, Sweden
🇸🇪
Skåne University Hospital, Dept. of Oncology, Lund, Sweden

and more 1 locations

Combined Beta- Plus Auger Electron Therapy Using a Novel Somatostatin Receptor Subtype 2 Antagonist Labelled With Terbium-161 (161Tb-DOTA-LM3)

Early Phase 1

Recruiting

Conditions: Neuroendocrine Neoplasia's (NENs)
Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET)

Interventions: Drug: 161Tb-DOTA-LM3
Drug: 177Lu-DOTATOC

First Posted Date: 2022-05-03

Last Posted Date: 2024-04-19

Lead Sponsor: University Hospital, Basel, Switzerland

Target Recruit Count: 16

Registration Number: NCT05359146

Locations: 🇨🇭
Division of Nuclear Medicine, University Hospital Basel, Basel, Switzerland

177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs

Phase 2

Withdrawn

Conditions: Neuroendocrine Tumors
Carcinoid Tumor
Gastrinoma
Pulmonary Carcinoid Tumor
Gastroenteropancreatic Neuroendocrine Tumor
Vipoma
Insulinoma

Interventions: Drug: 177Lu-DOTATOC

First Posted Date: 2021-06-07

Last Posted Date: 2023-02-21

Lead Sponsor: British Columbia Cancer Agency

Registration Number: NCT04915144

Locations: 🇨🇦
BC Cancer, Vancouver, British Columbia, Canada

Phase-II Study of Lu177DOTATOC in Adults With STTR(+)Pulmonary, Pheochromocytoma, Paraganglioma, Unknown Primary, Thymus NETs (PUTNET), or Any Other Non-.GEP-NET.

Phase 2

Withdrawn

Conditions: Pulmonary Neuroendocrine Neoplasm
Pheochromocytoma
Unknown Primary Tumors
Paraganglioma
Neuroendocrine Neoplasm of Ovary
Thymus Carcinoid
Neuroendocrine Carcinoma Metastatic
Neuroendocrine Tumors
Neuroendocrine Skin Carcinoma
Neuroendocrine Breast Tumor

Interventions: Drug: 177Lu-DOTATOC

First Posted Date: 2020-02-19

Last Posted Date: 2023-03-10

Lead Sponsor: Excel Diagnostics and Nuclear Oncology Center

Registration Number: NCT04276597

Locations: 🇺🇸
Excel Diagnostics and Nuclear Oncology Center, Houston, Texas, United States

Personalized CAPTEM Radiopeptide Therapy of Advanced, Non-resectable Neuroendocrine Cancer

Phase 2

Conditions: Neuroendocrine Tumors

Interventions: Drug: 177Lu-DOTATOC

First Posted Date: 2019-12-11

Last Posted Date: 2020-11-04

Lead Sponsor: University of Warmia and Mazury

Target Recruit Count: 25

Registration Number: NCT04194125

Locations: 🇵🇱
Centrum Diagnostyczno-Lecznicze Gammed, Warszawa, Poland

Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients

Phase 3

Active, not recruiting

Conditions: Neuroendocrine Tumors

Interventions: Drug: 177Lu-edotreotide PRRT
Drug: Everolimus
Other: Amino-Acid Solution

First Posted Date: 2017-02-09

Last Posted Date: 2023-11-30

Lead Sponsor: ITM Solucin GmbH

Target Recruit Count: 309

Registration Number: NCT03049189

Locations: 🇦🇹
Allgemeines Krankenhaus Wien, Wien, Austria
🇵🇱
"Gammed" Izabela Chuchrowksa, Warsaw, Poland
🇨🇭
Inselspital, Universitätsspital Bern, Bern, Switzerland

and more 49 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy